Research into Bosutinib

FDA accepts Pfizer leukemia treatment for review

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells - Research from Austria

Early Phase II Results Show Bosutinib Safe, Effective for CML - Press release from MD Anderson

Targeted therapy in chronic myeloid leukemia. - MD Anderson overview

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors - abstract from Nature

Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors. - abstract from American Society of Clinical Oncology annual meeting in 2007. Concluded that bosutinib was well tolerated.

Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones - mentions several TKIs under development for CLL patients.

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells - Wyeth Research paper abstract

Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia. - Wyeth Research

Valproic acid enhances bosutinib cytotoxicity in colon cancer cells.

Control of mammary tumor differentiation by SKI-606 (bosutinib) - some success in breast cancer.